These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report. Kedar A; Cohen ME; Freeman AI Cancer Treat Rep; 1978 May; 62(5):819-21. PubMed ID: 207427 [TBL] [Abstract][Full Text] [Related]
3. Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II. Becher R; Schütt P; Osieka R; Schmidt CG J Cancer Res Clin Oncol; 1980; 96(2):219-22. PubMed ID: 6248563 [TBL] [Abstract][Full Text] [Related]
7. [Neuropathy caused by cisplatin. 7 cases including one with an autopsy study]. Amiel H; Gherardi R; Giroux C; Salama J; Bréau JL; Delaporte P Ann Med Interne (Paris); 1987; 138(2):96-100. PubMed ID: 3034113 [TBL] [Abstract][Full Text] [Related]
8. Peripheral neuropathy after cis-platinum (II) (DDP) therapy. Reinstein L; Ostrow SS; Wiernik PH Arch Phys Med Rehabil; 1980 Jun; 61(6):280-2. PubMed ID: 6246848 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cavaletti G; Marzorati L; Bogliun G; Colombo N; Marzola M; Pittelli MR; Tredici G Cancer; 1992 Jan; 69(1):203-7. PubMed ID: 1309303 [TBL] [Abstract][Full Text] [Related]
10. [Peripheral neuropathy caused by cisplatin in patients with lung cancer]. Murata M; Yamaji Y; Futami H; Shimada Y; Fujita J; Hashimoto Y; Shiotani T; Irino S Gan To Kagaku Ryoho; 1989 Jun; 16(6):2283-8. PubMed ID: 2544151 [TBL] [Abstract][Full Text] [Related]
13. Advanced bladder cancer: therapy with cis-dichlorodiammineplatinum(II), adriamycin, and 5-fluorouracil. Williams SD; Donohue JP; Einhorn LH Cancer Treat Rep; 1979; 63(9-10):1573-6. PubMed ID: 498156 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of cis-dichlorodiammineplatinum(II) in cancer of the bilharzial bladder. Gad-el-Mawla N; Chevlen E; Hamza R; Ziegler JL Cancer Treat Rep; 1979; 63(9-10):1577-8. PubMed ID: 498157 [No Abstract] [Full Text] [Related]
15. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605 [TBL] [Abstract][Full Text] [Related]
16. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208 [TBL] [Abstract][Full Text] [Related]
17. Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Goodnight JE; Moseley HS; Eilber FR; Sarna G; Morton DL Cancer Treat Rep; 1979; 63(11-12):2005-7. PubMed ID: 393385 [TBL] [Abstract][Full Text] [Related]
18. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion. Lokich JJ Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073 [TBL] [Abstract][Full Text] [Related]
19. cis-Platinum combination chemotherapy of bladder cancer: an update. Williams SD; Einhorn LH; Donohue JP Cancer Clin Trials; 1979; 2(4):335-8. PubMed ID: 394869 [TBL] [Abstract][Full Text] [Related]